Abstract
PURPOSE: Antihypertensive therapy may improve bevacizumab efficacy in cancer patients. We examined efficacy and toxicity of angiotensin system inhibitors (ASI) and other antihypertensive drugs in bevacizumab treated recurrent glioblastoma patients.
METHODS: We retrospectively combined a national prescription registry with a clinical database with recurrent glioblastoma patients (n = 243).
RESULTS: Patients who initiated ASI after bevacizumab (n = 26) showed a tendency towards improved progression-free survival and overall survival (OS) with hazard rate (HR) reductions (HR = 0.70 and HR = 0.79, respectively). Calcium antagonists during bevacizumab therapy significantly improved OS (HR = 0.57).
CONCLUSIONS: Overall the study supports a potential beneficial effect of antihypertensive treatment on prognosis of bevacizumab treated glioblastoma patients.
| Original language | English |
|---|---|
| Journal | Cancer Investigation |
| Volume | 36 |
| Issue number | 9-10 |
| Pages (from-to) | 512-519 |
| Number of pages | 8 |
| ISSN | 0735-7907 |
| DOIs | |
| Publication status | Published - 26 Nov 2018 |
Keywords
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors/therapeutic use
- Bevacizumab/therapeutic use
- Brain Neoplasms/drug therapy
- Female
- Glioblastoma/drug therapy
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local/drug therapy
- Prognosis
- Progression-Free Survival
- Retrospective Studies
- Young Adult
